TrialsgrambetaRCTs are beautiful

ARCH

2017

Active-controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk

In 4,093 postmenopausal women with high fracture risk, romosozumab followed by alendronate reduced new vertebral, clinical and hip fractures compared with alendronate alone.

Result

Primary endpoint: New vertebral fracture

Vertebral fracture −48 %; clinical fracture −27 %; hip fracture −38 %. Excess serious CV events in the romosozumab arm (2.5 % vs 1.9 %).

Original publication
Subtopic
Romosozumab
Design
Active-controlled RCT, 24 mo
Relevance
Important: one of several pillars.
Source
Saag KG, et al. N Engl J Med. 2017;377(15):1417-1427.doi 10.1056/NEJMoa1708322

Discussion & critique

Anabolic-then-antiresorptive sequence beats antiresorptive alone, but the CV signal restricts use in patients with recent MI or stroke.

Discussed in podcasts